Amneal Pharmaceuticals Inc. announced that it has signed a long-term license agreement with Orion Corporation to commercialize a number of Amneal's complex generic products. Under the partnership agreement, Orion is Amneal's exclusive partner to bring its portfolio of complex generic programs to most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include a mix of generic products commercially available in the U.S., as well as select high-value pipeline products currently under development.

Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years.